Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,369
Recruiting: 3,967
Ph III recruiting: 537
Growth YoY: +9.4%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,405)

clinicaltrialsPublishedShowing 451–500 of 1,037 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06106308	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	active not recruiting	Phase 2	110	Cardiff OncologyINDUSTRY	1	Jun 16, 2026	clinicaltrials
NCT06501976	An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment	active not recruiting	Phase 2	9	Cancer Institute and Hospital, Chinese Academy of Medical Sciences